Lipid pathway deregulation in advanced prostate cancer

Galbraith, L., Leung, H. Y. and Ahmad, I. (2018) Lipid pathway deregulation in advanced prostate cancer. Pharmacological Research, 131, pp. 177-184. (doi:10.1016/j.phrs.2018.02.022) (PMID:29466694)

[img]
Preview
Text
158338.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives.

494kB

Abstract

The link between prostate cancer (PC) development and lipid metabolism is well established, with AR intimately involved in a number of lipogenic processes involving SREBP1, PPARG, FASN, ACC, ACLY and SCD1. Recently, there is growing evidence implicating the role of obesity and peri-prostatic adipose tissue (PPAT) in PC aggressiveness and related mortality, suggesting the importance of lipid pathways in both localised and disseminated disease. A number of promising agents are in development to target the lipogenic axis in PC, and the likelihood is that these agents will form part of combination drug strategies, with targeting of multiple metabolic pathways (e.g. FASN and CPT1), or in combination with AR pathway inhibitors (SCD1 and AR).

Item Type:Articles
Keywords:Lipid, metabolism, prostate cancer.
Status:Published
Refereed:No
Glasgow Author(s) Enlighten ID:Ahmad, Dr Imran and Leung, Professor Hing and Galbraith, Dr Laura
Authors: Galbraith, L., Leung, H. Y., and Ahmad, I.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Pharmacological Research
Publisher:Elsevier
ISSN:1043-6618
ISSN (Online):1096-1186
Published Online:18 February 2018
Copyright Holders:Copyright © 2018 Elsevier Ltd.
First Published:First published in Pharmacological Research 131: 177-184
Publisher Policy:Reproduced in accordance with the publisher copyright policy

University Staff: Request a correction | Enlighten Editors: Update this record